Helen Kuhlman, PhD
Operating Advisor
Helen supports the team in investment sourcing and scientific due diligence, with a particular focus on Europe. She is currently the Chief Business Officer of Evgen Pharma, an oncology-focused biotech in the UK, as well as an independent board member of the University Commercialization Executive Board at the University of Bath. Helen began her career as a research scientist at Cambridge Antibody Technology and Domantis, before transitioning into strategy and business development roles. She has also held innovation roles in governmental and quasi-governmental organizations—including at the South West of England Regional Development Agency and Development Bank of Wales—culminating in leading the creation and delivery of the UK’s £180m Biomedical Catalyst scheme. Helen has a PhD in Cell Physiology and Pharmacology from the University of Leicester, and a BSc in Biomedical Science from the University of Portsmouth.
Which Immune Cell Would Helen Be?
